Does Losartan/HCTZ Cause Sexual Dysfunction?
Losartan combined with hydrochlorothiazide (HCTZ) can cause sexual dysfunction, primarily due to the HCTZ component, though the risk is lower than with older antihypertensive agents and appears dose-dependent.
Understanding the Risk Profile
The sexual dysfunction risk with losartan/HCTZ is primarily attributable to the thiazide diuretic component rather than the ARB (angiotensin receptor blocker). According to major hypertension guidelines, thiazide diuretics—particularly at higher doses—have been associated with increased sexual dysfunction, especially erectile problems 1. The JNC 7 report specifically notes that "some reports have described an increased degree of sexual dysfunction when thiazide diuretics, particularly at high doses, are used" 1.
However, the evidence shows important nuances:
Dose matters significantly: The sexual dysfunction risk is substantially higher with doses ≥50 mg of hydrochlorothiazide or ≥25 mg of chlorthalidone 1. The standard losartan/HCTZ combination uses only 12.5-25 mg of HCTZ, which is at the lower end of the therapeutic range.
Time-dependent effects: In the TOMHS trial, patients on chlorthalidone reported significantly higher erectile problems through 24 months, but by 48 months the incidence was similar to placebo 1, suggesting potential adaptation or confounding factors.
ARBs vs. Other Antihypertensives
The losartan component itself is among the least likely antihypertensive agents to cause sexual dysfunction. Clinical endocrinology guidelines clearly state that "dysfunction with angiotensin-converting enzyme inhibitors or calcium channel blockers is less common" compared to older agents like beta blockers, reserpine, guanethidine, and hydralazine 2. While these guidelines specifically mention ACE inhibitors, ARBs share similar mechanisms and sexual dysfunction profiles.
The 2017 ACC/AHA guidelines acknowledge that "beta blockers, mineralocorticoid receptor antagonists, and other antihypertensive drugs can have negative effects on libido and erectile function," but notably do not list ARBs among the problematic agents 3.
Clinical Implications
When evaluating sexual dysfunction in patients on losartan/HCTZ:
Assess baseline function: Sexual dysfunction is extremely common in hypertensive patients independent of medication—hypertension itself causes endothelial dysfunction that impairs erectile function 2, 3.
Consider the HCTZ dose: If sexual dysfunction develops, the 12.5 mg HCTZ dose in standard combination tablets is less likely to be causative than higher doses. However, even low-dose thiazides can contribute in susceptible individuals.
Evaluate other factors: Look for diabetes, cardiovascular disease, smoking, alcohol use, other medications (especially beta blockers if combined therapy), and psychological factors 2.
Don't automatically discontinue: The cardiovascular benefits of blood pressure control outweigh the sexual dysfunction risk in most patients. Moreover, uncontrolled hypertension itself worsens sexual function through vascular mechanisms.
Management Strategy
If sexual dysfunction occurs on losartan/HCTZ:
First-line approach: Add a phosphodiesterase-5 inhibitor (sildenafil, tadalafil, vardenafil) rather than changing antihypertensive therapy 3, 4. These agents are safe with ARBs and diuretics (though absolutely contraindicated with nitrates) and address both medication-related and disease-related erectile dysfunction.
Alternative strategy: If PDE-5 inhibitors are contraindicated or ineffective, consider switching to losartan monotherapy at a higher dose (100 mg) or adding a calcium channel blocker instead of HCTZ, as CCBs have minimal sexual dysfunction risk 2.
Avoid: Do not switch to beta blockers or higher-dose diuretics, as these have higher sexual dysfunction rates.
Important Caveats
The evidence specifically linking the losartan/HCTZ combination to sexual dysfunction is limited—most data comes from studies of thiazide diuretics in general or other drug combinations. The FDA label for losartan does not list sexual dysfunction as a specific adverse effect 5, though this may reflect underreporting rather than true absence of effect.
Bottom line: While losartan/HCTZ can cause sexual dysfunction (primarily from the HCTZ component), the risk is lower than with many other antihypertensive regimens, particularly at the standard 12.5 mg HCTZ dose. The combination remains appropriate first-line therapy, with PDE-5 inhibitors available as effective adjunctive treatment if sexual dysfunction develops.